Next Phase Newsletter

An investment firm headquartered in Seoul, Korea, has established a US office in Boston to focus on US-based biotechnology companies. The firm invests from their third fund of $500 million. The firm is interested in opportunities at all stages of development and can allocate from $500 K up to $20 M in equity investments, acting as a lead or follow on.

The firm is currently focusing on the areas of immuno-oncology, gene therapy, ophthalmology, and platform technologies. Recent investments include companies targeting clinical stage small molecule therapeutics for oncology, peptide drugs for inflammatory diseases, and delivery methods and therapeutics in ophthamlology.

The story behind the company and management team is important to this firm. They look for a cohesive business plan and strategy, and are especially interested in opportunities with potential to expand into the Korean market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A laboratory science and services company makes venture investments in early stage companies that could enrich the firm’s future pipelines, as well as connect with more mature companies that may be targets for M&A. For venture rounds, the firm co-invests with other venture firms and will typically contribute in the range of $2-5 M for Series A, and $5-6 M for Series B and/or C. Overall, the firm will contribute $10-15 M throughout the lifetime of the investment. The firm typically makes around 2 investments per year.

The firm looks for opportunities related to research tools, diagnostics, centralized labs, and CROs that address the areas of toxicology, forensics, food and supplement testing, biopharmaceutical services, and molecular diagnostics. Some particular indications of interest are hematology, oncology, pain management, cardiology, and behavioral health. The firm is also interested in opportunities related to animal health.

The firm looks for an established management team and defined strategic plan for their raised capital. For venture investments, there should be pre-clinical data or prototypes available. If the company is a university spin-out, there should be some data acquired outside the academic setting already.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A healthcare focused venture capital firm based in China, with offices in Shanghai and Beijing, makes venture investments in early and growth stage companies and occasionally invests in PIPE deals. The firm recently raised a USD 300 million fund in 2014. The firm is flexible regarding the investment size; the firm can invest anywhere from several hundred thousand dollars up to USD 10 million or more. The firm generally invests in Chinese companies but will look at opportunities from around the world. The firm is actively seeking new investment opportunities.

The firm invests opportunistically in the life sciences. The firm is interested in biopharmaceuticals, medical devices, diagnostics, and mobile/digital health. For therapeutics, the firm considers all molecules and biologics, including biosimiliars and reformulated drugs. In terms of stage of development, the firm looks for products in early to late stages of clinical trials. For medical devices, the firm considers all classes of devices and generally looks for devices in later stages of development or close to market.

The firm invests in both private and public companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The venture and expansion capital arm of a US-based wealth management firm is investing from a 2014-vintage fund, and has around $270 million in total assets under management. The firm is current seeking new opportunities in the healthcare space. The firm’s initial equity investment range from $3-7 million, but are typically $12-$15 million total through subsequent rounds. The firm will only consider investment into US based firms.

The firm is currently most interested in the healthcare IT companies, but will also make select investments into later-stage medtech and diagnostic technologies that have no regulatory or reimbursement risk and proven commercial traction.

The firm generally invests in series A, B and C rounds. For HCIT businesses, the firm typically looks for companies with $3 million or more of revenue. As for medtech and diagnostics, the firm is opportunistic given the technology is post-approval and reimbursement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Venture Capital company founded in 2006 is currently making investments out of its 2nd fund that had its first close in 2013. The firm makes primarily equity investment into seed and early stage rounds ranging from $500,000 to $1 million initially and up to $1.5 million over the lifetime of the investment. The firm is focused on companies located in the Southwestern United States although they are open to review companies from throughout the US. The firm could make as many as 3 new investments over the next 6-9 months.

The firm is looking for companies in sectors of Therapeutics, Diagnostics, Medical Devices, Life Science Tools and Healthcare IT. The firm is agnostic in terms of subsectors and indications within these areas and is also interested in orphan indications and wireless medical devices. The firm looks to invest in very early pre-clinical stage companies and prefers to see some supporting in-animal data, although it is not a requirement.

The firm is looking for privately held companies with experienced management teams. The firm looks to play an active role as an investor and generally looks to take a board or board observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An evergreen private equity firm launched by a wealthy European family is headquartered in Paris, France with additional offices in China and the USA. The firm was created with an aim to invest in high growth opportunities in healthcare and multiple other sectors outside of retail. The firm typically makes minority investments of US$2-10 million in Series A and B rounds (either as lead or co-investor in a round), and is currently seeking new opportunities in France, United States, and China.

Within healthcare, the firm is interested in healthcare IT applications that improves quality or efficiency of care, such as telemedicine, patient-doctor interface workforce coordination, and analytics software. The firm prefers enterprise solutions, but can also consider consumer products. The firm is not interested in insurance, cosmetics, nutraceutical or well-being products. For hardware devices to be considered, it must have a strong software/data component as its core technology. The firm is agnostic to disease areas and is currently most interested in elderly care. The firm prefers to work with growth-stage companies that are revenue-generating.

The firm is looking for companies formed by a team of founders with expertise in the medical, technology, and sales and marketing sectors. One-person companies are less likely to be considered. The firm seeks teams that are able to work across cultures and grow into international markets. The firm is a long-term investor that works closely with its portfolio companies and strives to create a sharing culture together.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based out of Palo Alto, California is investing from a fund closed in 2015. The firm is flexible in terms of capital structure and seeks to lead Series A rounds in the $2M to $20M range with appropriate reserves for follow-on rounds. The firm is seeking to make 3 new investments within the next year. The firm is actively looking to invest in private companies, and will consider companies anywhere in the United States, but strongly prefers companies to be nearby San Francisco, New York or Boston.

The firm is interested in Healthcare IT, Wearable Devices, and Integrated Medical Devices. The firm is not interested in stand-alone device companies, and is only interested in devices with a software component. The firm may be interested in technology with a mobile app component, though that is not their focus. The firm will look at 510K devices only, though has a preference for technology that does not require FDA approval. The firm looks for disruptive technologies past prototype stage; it is not necessary for the technology to have FDA approval, but it must have solid data that shows its ability to drive valuable clinical outcomes. The firm has active interest and more inclination towards: cardiovascular/hypertension, obesity and weight loss, mental health, genetics, and heart failure.

The firm looks to invest in companies that have experienced management teams. The firm looks to take a board seat and play an active role in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com